

PRESS RELEASE

2010 third-quarter revenue

Villepinte, 9 November 2010

Consolidated Group revenue (IFRS):

In thousands of euros	2010	2009	Change
First quarter	86,684	79,031	+9.6%
Second quarter	92,220	83,485	+10.5%
Third quarter	82,797	81,997	+1.0%
First nine months	261,701	244,513	+7.0%

Consolidated revenue by region

In thousands of euros	2010	2009	Change
European subsidiaries.....	190,610	191,120	- 0,3%
Other markets.....	71,090	53,393	+33,1%
First nine months	261,701	244,513	+7,0%

2010 third-quarter sales highlights and full-year outlook

Dotarem made further gains in Europe in the third quarter (+4.2% in value) while Xenetix sales declined 12% in value. Particularly high sales volumes in the first half and production incidents before and after the summer shutdown, since resolved, reduced the availability of this product mainly in Europe during this quarter. Sales in regions outside Europe were up 23% in the quarter.

For the nine-month period ended 30 September sales grew 7% on gains by both Dotarem (+11.3%) and Xenetix (+6.5%), further boosted by changes in foreign exchange rates primarily in the second quarter.

For FY 2010, the Group maintains its guidance for annual growth in line with the prior year.

Contact: Administrative and Finance Department - Tel.: +33 (0)1 45 91 50 69